DHR - Danaher Corporation
A scientific instrument and diagnostics conglomerate whose portfolio of precision tools is essential to pharmaceutical manufacturing, life sciences, and environmental testing.
Finlify Score
43.0 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$196.17
-0.16%
52W Range
$160.93 - $242.80
Market Cap
$134.8B
-0.2%Compared to previous day
2026 Q1 Revenue
$6.0B
-13.0%Changes from last reporting quarter
2026 Q1 EPS
$1.00
Diluted shares
Analyst Rating
32 analysts in latest ratings feed
RSI
47.6
40-70 moderate
2Y Range Position
29%
-30.4% from high / +21.9% from low
Beta
0.77
Relative to market benchmark
MACD
-0.42
MACD line 1.94 / signal line 2.36
Fundamental Trend
Growth 13.1Financial Health
Quality 78.5Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
AVOID43.0 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $6.0B-13.0% | $6.8B+13.0% | $6.1B+2.0% | $5.9B+3.4% |
| Gross Profit | $3.6B-9.5% | $4.0B+12.6% | $3.5B0.0% | $3.5B+0.3% |
| Operating Income | $1.3B-10.5% | $1.5B+30.2% | $1.2B+51.8% | $760M-40.3% |
| Net Income | $1.0B-14.0% | $1.2B+31.8% | $908M+63.6% | $555M-41.8% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jul 25, 2026
The Finlify signal for DHR is AVOID, with a Finlify Score of 43.1/100. This appears to be primarily driven by a very low Fundamental Trend score and low Relative Strength, despite strong Accumulation/Volume and Financial Quality scores.
Technical
The Relative Strength score is quite low at 20.9/100, which may indicate underperformance compared to other assets. However, the Accumulation/Volume score is strong at 90.3/100, suggesting some buying interest. The asset has seen a 6.6% return over 60 days but remains 20.5% below its 52-week high, with its RSI(14) at a neutral 51.1.
Fundamentals
The Fundamental Trend score is notably low at 13.1/100, which could suggest deteriorating fundamental prospects, despite a high Financial Quality score of 78.5/100. Valuation metrics appear elevated, with a P/E ratio of 37.4x and a P/S ratio of 5.5x. The asset offers a modest dividend yield of 0.83% and has a beta of 0.8, indicating potentially lower volatility than the broader market.
Macro Context
The macro environment shows inflation metrics like CPI YoY at 3.7% and Core PCE at 3.4%, which could influence future interest rate decisions. A 10Y Treasury Yield of 4.7% and a positive yield spread of 0.4% may suggest a less restrictive monetary policy outlook, potentially impacting growth-oriented sectors like Life Sciences Tools & Services.
Key Risks
- The very low Fundamental Trend score of 13.1/100 suggests potential underlying issues with the company's fundamental trajectory.
- Elevated valuation multiples, such as a P/E of 37.4x and P/S of 5.5x, may indicate the asset is priced for significant future growth.
- A low Relative Strength score of 20.9/100 could signal underperformance against its peers or the broader market.